Exact Sciences Corporation
General ticker "EXAS" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $10.0B (TTM average)
Exact Sciences Corporation follows the US Stock Market performance with the rate: 45.6%.
Estimated limits based on current volatility of 0.1%: low 103.23$, high 103.53$
Factors to consider:
- Total employees count: 7000 as of 2024
- US accounted for 93.1% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Lack of profitability, Market competition, Operational and conduct risks, Senior management dependency, Liquidity and credit risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [63.83$, 110.05$]
- 2026-12-31 to 2027-12-31 estimated range: [56.08$, 99.32$]
Financial Metrics affecting the EXAS estimates:
- Negative: with PPE of 2541.8 at the end of fiscal year the price was high
- Positive: -4.75 < Operating profit margin, % of -2.96
- Positive: Investing cash flow per share per price, % of 1.02 > -0.63
- Positive: 0.01 < Operating cash flow per share per price, % of 2.56
- Positive: Inventory ratio change, % of -0.69 <= 0
- Positive: Interest expense per share per price, % of 0.17 <= 0.73
Short-term EXAS quotes
Long-term EXAS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2,578.19MM | $2,758.87MM | $3,246.99MM |
| Operating Expenses | $2,793.20MM | $3,807.57MM | $3,346.07MM |
| Operating Income | $-215.01MM | $-1,048.70MM | $-99.08MM |
| Non-Operating Income | $13.27MM | $12.54MM | $-104.81MM |
| Interest Expense | $19.45MM | $31.97MM | $32.87MM |
| R&D Expense | $425.88MM | $431.21MM | $523.00MM |
| Income(Loss) | $-201.75MM | $-1,036.16MM | $-203.89MM |
| Taxes | $2.40MM | $-7.30MM | $4.06MM |
| Profit(Loss)* | $-204.15MM | $-1,028.86MM | $-207.95MM |
| Stockholders Equity | $3,145.30MM | $2,402.25MM | $2,401.05MM |
| Inventory | $127.47MM | $162.38MM | $166.20MM |
| Assets | $6,471.33MM | $5,928.14MM | $5,860.63MM |
| Operating Cash Flow | $156.12MM | $210.54MM | $491.44MM |
| Capital expenditure | $124.19MM | $135.99MM | $134.66MM |
| Investing Cash Flow | $49.68MM | $-442.15MM | $195.12MM |
| Financing Cash Flow | $159.77MM | $231.87MM | $-338.09MM |
| Earnings Per Share** | $-1.13 | $-5.59 | $-1.10 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.